DEVELOPMENT STRATEGY
Which indication, cohort, or geography deserves priority?
Connect disease, biomarker, competitive, population, and access evidence into scenario risks and development priorities.
APPLICATIONS
One intelligence layer, applied to the decisions that shape oncology development.
Applications are decision contexts, not separate products. The evidence dimensions and review standards remain connected across the program.
Start with the decision that is material now.
A focused scope can expand only after the first signal proves useful.
TRIAL DESIGN + PLANNING
Which protocol assumptions are most fragile?
Pressure-test cohort logic, treatment context, competitive trial pressure, and operational consequences before execution hardens.
SITE + INVESTIGATOR
Which candidates deserve diligence first?
Combine institutional capability, PI relevance, competitive burden, geography, and patient opportunity into a reviewed priority map.
PATIENT OPPORTUNITY
Does the proposed population exist where the plan expects it?
Use public burden and access proxies, geography, biomarker context, and licensed clinical evidence where permitted.
CRO / INTERNAL VALIDATION
What does an independent signal add to the current view?
Compare overlap, incremental candidates, underweighted evidence, contradictions, and decision impact without attacking execution partners.
CONTINUOUS INTELLIGENCE
What changed since the last decision?
Track trials, readouts, sites, investigator affiliations, competitive activity, and confidence as the development program evolves.
The evidence trail evolves with the program instead of restarting at each gate.
Disease + strategy intelligence
Frame the opportunity, assumptions, scenarios, and material uncertainties.
Trial + site + PI + patient intelligence
Turn protocol context into a prioritized diligence plan.
Enrollment risk + changing competition
Update the evidence as operational reality and the competitive landscape change.
Continuous intelligence
Preserve the evidence and review history across related decisions.
A first pilot is scoped around one asset or protocol, one material decision, one geography or cohort, and pre-agreed success criteria.
START WITH ONE DECISION
A focused pilot begins with a fixed question.
The first engagement is designed to produce an independent signal that can be compared with the sponsor's or CRO's current view.
Outputs are for strategic planning and do not guarantee patient availability, enrollment, site performance, regulatory outcomes, or clinical success.